Review Links Sleep-Disordered Breathing, Cognitive Impairment

Share this content:
Review Links Sleep-Disordered Breathing, Cognitive Impairment
Review Links Sleep-Disordered Breathing, Cognitive Impairment

WEDNESDAY, Aug. 30, 2017 (HealthDay News) -- Sleep-disordered breathing (SDB) is associated with increased likelihood of cognitive impairment, according to a review published online Aug. 28 in JAMA Neurology.

Yue Leng, Ph.D., from the University of California in San Francisco, and colleagues examined the correlation between SDB and risk of cognitive impairment in a systematic review. Data were included from cross-sectional and prospective studies with at least 200 participants (mean age, 40 years or older). Fourteen studies were included, of which six were prospective. The studies covered 4,288,419 men and women.

The researchers found that in pooled analysis of the six prospective studies, those with SDB were more likely to develop cognitive impairment (risk ratio, 1.26; 95 percent confidence interval, 1.05 to 1.5), with no indication of publication bias but significant heterogeneity between studies. The pooled risk ratio was 1.35 (95 percent confidence interval, 1.11 to 1.65) after the researchers removed one study that introduced significant heterogeneity. In pooled analysis of the seven cross-sectional studies, those with SBD had worse executive function (standard mean difference, −0.05; 95 percent confidence interval, −0.09 to 0), with no indication of heterogeneity or publication bias. There was no correlation between SDB and global cognition or memory.

"Further studies are required to determine the mechanisms linking these common conditions and whether treatment of SDB might reduce risk of cognitive impairment," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »